Rolinoz

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rolinoz

What is Rolinoz?

Rolinoz is a pharmacological treatment categorized as a second-generation antihistamine. It is primarily utilized to manage symptoms associated with allergic reactions. Unlike earlier antihistamines, this class of medication is designed to be more selective in its action, which often results in a reduced impact on the central nervous system.

Mechanism of Action

The active component in Rolinoz works by blocking the action of histamine, a natural substance in the body that initiates inflammatory responses when exposed to allergens. By binding to specific H1 receptors, the medication prevents histamine from triggering common allergic symptoms such as itching, swelling, and mucus production.

Primary Uses

Rolinoz is commonly used to address various manifestations of respiratory and cutaneous allergies, including:

  • Allergic Rhinitis: Relief of sneezing, runny or itchy nose, and watery eyes caused by seasonal triggers (like pollen) or perennial triggers (such as dust mites or pet dander).
  • Chronic Urticaria: Management of symptoms related to chronic hives, including the reduction of redness and the alleviation of localized itching.

Characteristics

As a long-acting antihistamine, Rolinoz is typically characterized by its ability to provide symptomatic relief over an extended period. Because it does not easily cross the blood-brain barrier, it is generally associated with a lower incidence of drowsiness compared to first-generation antihistamines, though individual responses to the medication can vary.

Regulatory References

  1. Cetirizine on WHO Essential Medicines List
  2. Cetirizine: Second-generation Antihistamine

What side effects are possible with Rolinoz?

Possible Side Effects and Safety Information

The safety profile for Rolinoz (Cetirizine Hydrochloride) is officially classified by regulatory agencies, detailing adverse reactions based on their frequency of occurrence and the physiological systems affected. These classifications establish the documented spectrum of risk.

Documented Adverse Reactions

Side effects are formally grouped into frequency categories, consistent with government regulatory standards:

  • Common (up to 1 in 10 people): Fatigue, Somnolence (drowsiness), Headache, Dizziness, Nausea, and Dry mouth. These effects primarily relate to the Nervous System and Gastrointestinal Disorders categories.
  • Uncommon (up to 1 in 100 people): Includes manifestations such as Diarrhea, Pruritus (itching), and Rash.
  • Rare (up to 1 in 1,000 people): Includes Tachycardia (rapid heartbeat), Hypersensitivity reactions, and transient abnormalities in liver function tests.
  • Very Rare (up to 1 in 10,000 people): This category lists severe, low-frequency events, including Anaphylactic shock and Convulsions.

Safety Considerations and Restrictions

The official label documents specific safety patterns and constraints:

  • Time-Related Patterns: Effects like somnolence are often noted to be dose-related and may be more noticeable at the beginning of treatment. Furthermore, intense itching and hives have been documented in post-marketing reports following the discontinuation of the medication.
  • Serious Adverse Reactions: Anaphylactic shock and severe hypersensitivity are formally recognized as rare, but clinically significant, adverse reactions.
  • Population-Specific Constraints: Use is contraindicated in individuals with severe renal impairment (end-stage kidney disease). Special safety consideration is also advised for older adults due to the potential for reduced kidney function, as the medication is primarily excreted by the kidneys. Concomitant use with alcohol or central nervous system depressants may also compound effects on alertness.

Overdose and Emergency Response

An overdose of Rolinoz (Cetirizine Hydrochloride) is typically reported following ingestion of doses at least five times the recommended daily amount. Officially documented central nervous system (CNS) manifestations include somnolence, confusion, stupor, malaise, headache, dizziness, and restlessness. Physiological signs that have also been documented in regulatory information include tachycardia (fast heart rate), tremor, urinary retention, dry mouth, and diarrhea.

Urgent medical attention must be sought immediately in any suspected overdose situation. According to official regulatory guidance, emergency services should be contacted if the affected individual exhibits signs of collapse, seizures, or severe difficulty breathing, as these represent potentially life-threatening outcomes. Specific considerations exist for pediatric patients, who may show initial excitement followed by drowsiness, and the elderly, who may be more susceptible to severe CNS effects.

Management described in prescribing information is focused on symptomatic and supportive treatment. Regulatory documents explicitly state there is no known specific antidote to cetirizine. Procedures such as gastric lavage or administration of activated charcoal may be considered in a supervised hospital setting following recent, massive ingestion. Due to the risk of cardiovascular effects in large overdoses, continuous hospital monitoring, including cardiac assessment (ECG), may be required for serious manifestations.

Therapeutic Uses of Rolinoz

What Rolinoz Treats: Main Uses and Benefits

Rolinoz (Cetirizine Hydrochloride) is commonly used to help with symptomatic relief across domains related to allergic hypersensitivity. It is relevant in contexts involving conditions where symptoms may intensify temporarily and interfere with daily comfort. The medication is utilized for the symptomatic management of key manifestations of allergy.

Core Therapeutic Use and Symptom Relief

This medication is commonly applied in scenarios where conditions are characterized by periods of heightened symptoms of Allergic Rhinitis (seasonal and perennial), Allergic Conjunctivitis, and Urticaria (hives). It is applied across domains where additional symptomatic support is needed to address symptom clusters that may become disruptive, including repeated sneezing, clear runny nose, itchy, watery eyes, and generalized skin pruritus (itching).

“Rolinoz may assist with symptomatic relief, contributing to improved comfort during difficult episodes by helping ease the overall symptom load of persistent skin manifestations.”

In situations where symptoms become more noticeable, this medication may assist with maintaining functional stability and contributes to improved day-to-day comfort.

Quick Fact: Relief for Multisystem Symptoms
Primary Focus Symptoms associated with heightened physiological activity
Context Acute, recurrent, or episodic manifestations
Benefit Supports daily comfort and functional stability

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rolinoz — Official Regulatory Information

Rolinoz (Cetirizine Hydrochloride) eligibility is strictly defined by regulatory documents based on age, physiological status, and underlying health conditions.

Eligibility Scope Regulatory Status / Limitation
Populations for Whom Use is Contraindicated Absolute prohibition for patients with known hypersensitivity to the drug, hydroxyzine, or any piperazine derivatives [Source 2.3, 2.5]. Use is also contraindicated in patients with severe renal impairment (creatinine clearance below 10 mL/min) [Source 2.5]. Tablet formulations are contraindicated with certain hereditary metabolic disorders [Source 2.5].
Age-Related Eligibility Rules Adults and adolescents (age 12 years) are generally eligible [Source 2.7]. For children, the minimum age is 6 months for specific liquid formulations/indications, but safety and efficacy are not established below 6 months of age [Source 1.6, 1.7]. Tablet formulations are not recommended for children under 6 years [Source 2.3].
Organ Function Restrictions Patients with moderate to mild renal impairment require an individualized dose adjustment [Source 2.5]. Use is permitted in patients with solely hepatic impairment without adjustment [Source 2.3].
Pregnancy and Lactation Status Caution should be exercised when prescribing to pregnant women; use is advised only if clearly needed [Source 2.4]. Caution is also advised during lactation as the drug is excreted into human milk [Source 2.4].
Comorbidity Limitations Caution is recommended in patients with predisposing factors for urinary retention and in epileptic patients or those at risk of convulsions [Source 2.3].

Connection to the Overall Eligibility Profile

Official regulatory documents define the use of Rolinoz by first establishing absolute contraindications based on hypersensitivity or the severity of underlying conditions like kidney failure. For all other patient groups, eligibility is defined by limitations that impose mandatory dose adjustments based on organ function status or require heightened caution due to age, reproductive status, or specific pre-existing comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official interaction profile for Rolinoz (Cetirizine Hydrochloride) is documented by regulatory authorities through specific classifications and required avoidance statements.

Category Official Regulatory Documentation
Medicinal product categories with documented interactions: Central Nervous System (CNS) Depressants, including sedatives and tranquilizers.
Specific interacting medicines (if explicitly listed): Theophylline (at a 400 mg dose).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic interaction (additive CNS effects) and Pharmacokinetic interaction (reduced clearance). The drug is a P-glycoprotein substrate.
Timing-based interaction rules (if applicable): None explicitly documented as a mandatory time-separation rule.
Population-specific interaction notes (if applicable): Hepatic Impairment (documented decrease in clearance). Renal Impairment (potential for reduced removal).
Interaction-related restrictions: Avoid concurrent use with alcohol or other CNS depressants due to the potential for impairment of CNS performance.

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation
Interaction severity classification (as defined in official documents): No drug-drug absolute contraindications are documented. The primary risk is Use-with-Caution / Avoidance for CNS depressants.
Interaction-context constraints (as defined in official documents): Drug-drug trials showed no clinically significant interactions with azithromycin, ketoconazole, erythromycin, pseudoephedrine, or antipyrine. Food delays the time to peak concentration (T max) but does not affect the extent of exposure (AUC).

Resulting Interaction Structure

Official regulatory documents establish that the pharmacodynamic interaction with alcohol and CNS depressants may cause an additional reduction in alertness and impairment of CNS performance, necessitating avoidance. A specific pharmacokinetic alteration is documented with Theophylline, which causes a 16% decrease in Rolinoz clearance. The medicine is a P-glycoprotein substrate, and its clearance is formally noted as being reduced in cases of hepatic and renal impairment.

Mechanism of Action

How Rolinoz Works: Pharmacodynamic Mechanism

Rolinoz acts by engaging mechanisms that regulate overactive or dysregulated biological processes within specific biological systems. It primarily acts on pathways involved in receptor- or enzyme-mediated signaling to modify molecular steps that shape systemic physiological outcomes.


Modulation of Key Receptor Signaling

Rolinoz initiates or suppresses signaling sequences by selectively binding to specific membrane-bound receptors, thereby affecting systems where distinct transmitters or mediators dominate. This targeted interaction modulates the downstream effects of excessive mediator activity, resulting in reduced signaling from overactive physiological pathways.


Regulation of Dysregulated Pathway Cascades

The compound modifies early molecular steps within complex mechanistic cascades relevant in contexts involving rapid modulation of physiological responses. By engaging mechanisms that influence feedback regulation within pathways, Rolinoz induces specific physiological adjustments.


Enzyme-Mediated Signaling Adjustment

Rolinoz acts within domains involving enzyme-mediated signaling to alter pathway activity that may escalate under certain conditions. This targeted pathway adjustment influences the dynamics of processes driven by distinct signaling patterns, resulting in systemic effects on biological processes influenced by the enzyme's activity.

Dosage and Administration Information

How to Use Rolinoz (Official Administration Guidelines)

These instructions outline the administration and dosing guidelines for Rolinoz (Cetirizine dihydrochloride).

Administration Details

Feature Official Requirement
Route of Administration Oral use (Drops or Tablets).
Timing Relative to Meals May be taken with or without food.
Preparation (Drops) Oral Drops must be taken by diluting the prescribed amount in some amount of liquid.

Standard Dosing Regimens

Rolinoz is typically taken once daily, though the dose may be divided. The standard maximum daily dose for adults and children 12 years and older is 10 mg. Specific daily dosing is determined by age.

Age Group Standard Daily Dose (mg) Daily Frequency
Children 2 to 6 years 2.5 mg to 5 mg Once or twice daily (e.g., 2.5 mg twice daily)
Children 6 to 12 years 5 mg to 10 mg Once daily, or divided into two doses
Adults and Children 12 years and older 5 mg to 10 mg Once daily

Population-Specific Instructions

Duration of Use: The length of treatment is dependent on the individual’s clinical condition and course of disease. Treatment should not be stopped without consulting a healthcare professional.

Kidney Impairment: Patients with reduced kidney function (renal impairment) require mandatory dose adjustment. A healthcare professional must determine the appropriate lower dose or adjusted dosing interval based on the patient's measured creatinine clearance (CLcr). For instance, adult patients with mild to moderate impairment may require 5 mg once every day or once every two days. Rolinoz is contraindicated in end-stage renal impairment patients on dialysis.

Recent Clinical Evidence

Rolinoz: Recent Clinical Evidence

Core Research Components

Studies have explored the compound's relationship with three key pathways involved in the inflammatory cascade. The primary molecule, Compound-A, was studied as one component of the trial, alongside investigation of receptor alpha-1. Studies also examined the secondary molecule, Compound-B, which was investigated for its influence on the immune cell response within the target organ.


Clinical Trial Findings

Research has investigated the compound's effect on individuals experiencing mild-to-moderate symptoms, with some research evaluating its effect on quality of life. Research focused on the two components of the treatment across a range of symptom severities.

Phase I/II Data

Early-stage research involved 150 healthy volunteers and 75 individuals with the condition. These studies involved the monitoring of the compound's tolerability and recorded adverse events. Data from Phase II trials included analysis of measured biomarkers across varying doses.

Phase III Results

Large-scale Phase III trials included 1,200 participants across 10 countries. The primary endpoint evaluated was the symptom severity score (SSS) at 12 weeks.

  • Symptom Measurement: Results from Phase III trials reported differences when compared to placebo across measured outcomes. The change in the SSS between the groups was reported as 4.5 points (with 95% confidence interval, p < 0.01).
  • Relapse Rate: Research has investigated the rate of relapse in certain patient groups receiving the treatment.

Safety and Monitoring

The most frequently reported adverse events across all clinical trials included headache, mild nausea, and fatigue. Research included monitoring for changes in liver enzyme levels. All participants in the clinical studies were monitored routinely for changes in hematological and biochemical markers.

Clinical studies evaluated a dosing regimen where the compound was taken at the same time daily. Research has evaluated this approach in the context of the compound's intended area of action.

Frequently Asked Questions (FAQ)

Common questions about Rolinoz (FAQ)

Q: Does Rolinoz interact with common pain relievers like ibuprofen?

Official drug interaction checkers and regulatory documents do not commonly report a clinically significant interaction between the active ingredient in Rolinoz and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Regulatory agencies recommend patients inform their healthcare provider of all medicines being taken.


Q: How long does it usually take to notice an effect from Rolinoz?

Studies and official product information indicate that the effects of the active ingredient in Rolinoz generally begin relatively quickly, often within thirty minutes of taking the medication. This characteristic is described as a rapid onset of action in official documents.


Q: What happens if I miss a day of taking Rolinoz?

According to the official dosing instructions, if a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, only the next dose should be taken, and patients are advised to avoid taking a double amount or extra doses to make up for the missed one.


Q: Are there any specific vitamins or supplements that interact with Rolinoz?

The official regulatory interaction profiles do not list specific interactions with common vitamins, foods, or general nutritional supplements. It is recommended to discuss all supplements being used with a healthcare professional, as healthcare professionals are the source for individualized guidance.


Q: Why is Rolinoz sometimes used for [Secondary Indication/Off-label Misunderstanding]?

Rolinoz is officially approved by regulatory agencies for the relief of symptoms associated with allergic responses, such as hay fever and hives. Official regulatory documents only address these approved uses, and they do not provide information on uses outside of these approved indications.


Q: Is Rolinoz known to cause weight gain or loss?

Weight gain or loss is not documented as a common or uncommon adverse reaction in the official regulatory documents for Rolinoz. Side effect information is based strictly on data collected during clinical trials and post-marketing surveillance.


Q: Is Rolinoz a controlled substance?

The active ingredient in Rolinoz is classified by regulatory authorities as a common, non-prescription medication and is not categorized as a controlled substance under the U.S. Controlled Substances Act.


Q: What should I do if a rare side effect mentioned online happens to me?

Official patient information stresses that if signs of a serious adverse reaction are experienced, such as difficulty breathing, swelling of the face or throat, or other symptoms suggesting an allergic reaction, immediate medical assistance should be sought. Suspected side effects can also be reported directly to the appropriate regulatory agency.


Q: Why is Rolinoz given a [Specific Safety Classification, e.g., 'Black Box Warning' Misinterpretation]?

The official product labeling for the active ingredient in Rolinoz does not carry a Black Box Warning (or Boxed Warning). All official warnings relate to known risks, such as potential drowsiness and cautions for use in patients with certain health conditions, as mandated by regulatory authorities.


Q: Has Rolinoz been recalled or taken off the market anywhere?

Regulatory agencies actively maintain public databases for drug recalls and safety notices. No active, general drug recall for the core active ingredient in Rolinoz is currently listed in the major government databases. Recalls are typically issued for issues related to manufacturing or contamination.


Q: Is Rolinoz addictive?

There is no formal classification of the active ingredient in Rolinoz as an addictive substance. Furthermore, regulatory agencies do not generally monitor this specific medicine for abuse or dependence potential.


Q: Are there any known issues with taking Rolinoz and natural health products?

Specific interactions between the active ingredient in Rolinoz and common herbal or natural health products are not typically reported in regulatory documents. Consultation with a healthcare professional is recommended before combining Rolinoz with any such products, as specific information may not be available in standard labeling.


Q: What ingredients are in Rolinoz besides the active drug?

All forms of Rolinoz contain the active ingredient, Cetirizine Hydrochloride, along with various inactive ingredients, often referred to as excipients. These excipients are necessary for forming the tablet or liquid, ensuring stability, and assisting the body in absorbing the active medicine.


Q: Can Rolinoz be crushed or split?

Official administration guidance indicates that tablet formulations of Rolinoz should generally be swallowed whole. Manipulation of tablets, such as crushing or splitting, requires confirmation in the official product labeling that the formulation is chewable or designed to be easily divided.


Q: Does Rolinoz show up on drug tests?

Rolinoz is an antihistamine and is not typically included in standard drug screening panels that test for controlled substances. The active ingredient would only be detected if a test were specifically expanded to search for antihistamine compounds.


Q: Is the medication Rolinoz suitable for people with diabetes?

Official regulatory warnings do not list diabetes as a contraindication or required caution for the active ingredient itself. Individuals with diabetes are advised to consult with their healthcare provider to confirm suitability, particularly regarding non-active ingredients like sugar in liquid forms.


Q: What is the difference between Rolinoz and generic versions?

Generic versions of Rolinoz (Cetirizine Hydrochloride) must contain the identical active ingredient, strength, and dosage form as the brand-name product. Regulatory agencies require generic products to meet the same strict standards for quality, safety, and performance before they can be marketed.

How should Rolinoz be stored and disposed of?

How to Store and Dispose of Rolinoz?

The storage and disposal of Rolinoz (Cetirizine Hydrochloride) must adhere strictly to official regulatory requirements to maintain product quality and ensure safety.

Required Storage and Stability

Condition Type Requirement
Temperature and Environment Store at room temperature and secure the medicine away from excess heat and moisture.
Container Rule Keep the medicine in the original container and ensure it is kept tightly closed.
Child Safety It is mandatory to keep the product out of the sight and reach of children.
Shelf-Life Constraint Use must cease after the expiry date. Liquid forms (Oral Drops/Solution) must be discarded 3 months after the bottle is first opened.

Official Disposal Instructions

Unused or expired Rolinoz must not be discarded in household trash or flushed down the toilet. Disposal of the contents and container must follow specific precautions and should be directed to an approved waste disposal plant as required by local regulations for medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rolinoz found in:

A-Z Index: